Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat
Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) re...
Gespeichert in:
Veröffentlicht in: | European journal of anaesthesiology 2002-07, Vol.19 (7), p.504-509 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 509 |
---|---|
container_issue | 7 |
container_start_page | 504 |
container_title | European journal of anaesthesiology |
container_volume | 19 |
creator | Ittner, K. P. Bucher, M. Zimmermann, M. Grobecker, H. F. Krämer, B. K. Taeger, K. |
description | Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) receptor agonists impair glucose metabolism. To evaluate a possible dose-dependent hyperglycaemic effect of urapidil due to its 5-HT1A receptor agonistic properties, the effect of three doses of urapidil on hyperglycaemia in the streptozotocin diabetic rat was investigated. Methods: Male Wistar-Kyoto rats were made diabetic by streptozotocin and randomly allocated to the following daily treatments for 7 days (n = 6 each): urapidil 6 mg kg−1, urapidil 20 mg kg−1, urapidil 60 mg kg−1, insulin 4 IU kg−1 subcutaneously. One diabetic group and one non-diabetic healthy group served as controls. Results: Treatment for 7 days with urapidil 20 mg kg−1 and urapidil 60 mg kg−01 reduced mean glucose concentrations significantly (urapidil-20: 15.6 ± 1.1 mmol L−1P = 0.023; urapidil-60: 15.8 ± 0.8 mmol L−1, P = 0.04) compared with diabetic controls (20.9 ± 0.8 mmol L−1), whereas those after urapidil 6 mg kg−1 were similar to diabetic controls. Insulin treatment normalized blood glucose concentrations. Conclusions: The α1-adrenoceptor antagonist/5-HT1A receptor agonist urapidil has no hyperglycaemic effect on experimental diabetes mellitus, even in high doses, despite its 5-HT1A receptor agonistic properties. |
doi_str_mv | 10.1017/S0265021502000820 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71893357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0265021502000820</cupid><sourcerecordid>1495616271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-49f7633922ed3af79419ad6ec4845f1d8c014a043ae92e56497c4a81f347dfb53</originalsourceid><addsrcrecordid>eNp1kU9r3DAQxUVJaDbbfoBcggg0Nyf6Z8k-lpCkhUAOSc9GlkZbLV5pK8mH5tNXSwwLLT0IwbzfezPMIHRByQ0lVN2-ECZbwmh9hJCOkQ9oRblsG8aFPEGrg9wc9DN0nvO2Mm31fURnlNHKUb5C4d45MAVHh8vPBICtr4UEoWAbM-SDMCe999ZPOAY8TjFavJlmU1VsYjAVTbr4GDL2oYYAziXBvsS3WKKpJev1CMUbXLFP6NTpKcPn5V-jHw_3r3ffmqfnx-93X58awzkpjeidkpz3jIHl2qle0F5bCUZ0onXUdoZQoYngGnoGrRS9MkJ31HGhrBtbvkbX77n7FH_NkMuw89nANOkAcc6Dol3PeasqePUXuI1zCnW2gVHZ9lJVbo3oO2RSzDmBG_bJ73T6PVAyHC4x_HOJ6rlcgudxB_boWFZfgS8LoLPRk0s6GJ-PHFdckE5Wji_N9W5M3m7gOOL_2_8BS6GfkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216596793</pqid></control><display><type>article</type><title>Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Ittner, K. P. ; Bucher, M. ; Zimmermann, M. ; Grobecker, H. F. ; Krämer, B. K. ; Taeger, K.</creator><creatorcontrib>Ittner, K. P. ; Bucher, M. ; Zimmermann, M. ; Grobecker, H. F. ; Krämer, B. K. ; Taeger, K.</creatorcontrib><description>Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) receptor agonists impair glucose metabolism. To evaluate a possible dose-dependent hyperglycaemic effect of urapidil due to its 5-HT1A receptor agonistic properties, the effect of three doses of urapidil on hyperglycaemia in the streptozotocin diabetic rat was investigated. Methods: Male Wistar-Kyoto rats were made diabetic by streptozotocin and randomly allocated to the following daily treatments for 7 days (n = 6 each): urapidil 6 mg kg−1, urapidil 20 mg kg−1, urapidil 60 mg kg−1, insulin 4 IU kg−1 subcutaneously. One diabetic group and one non-diabetic healthy group served as controls. Results: Treatment for 7 days with urapidil 20 mg kg−1 and urapidil 60 mg kg−01 reduced mean glucose concentrations significantly (urapidil-20: 15.6 ± 1.1 mmol L−1P = 0.023; urapidil-60: 15.8 ± 0.8 mmol L−1, P = 0.04) compared with diabetic controls (20.9 ± 0.8 mmol L−1), whereas those after urapidil 6 mg kg−1 were similar to diabetic controls. Insulin treatment normalized blood glucose concentrations. Conclusions: The α1-adrenoceptor antagonist/5-HT1A receptor agonist urapidil has no hyperglycaemic effect on experimental diabetes mellitus, even in high doses, despite its 5-HT1A receptor agonistic properties.</description><identifier>ISSN: 0265-0215</identifier><identifier>EISSN: 1365-2346</identifier><identifier>DOI: 10.1017/S0265021502000820</identifier><identifier>PMID: 12113613</identifier><identifier>CODEN: EJANEG</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>(RD) Surgery ; Adrenergic alpha-Antagonists - administration & dosage ; Animals ; Biological and medical sciences ; Blood Glucose - drug effects ; Blood Pressure - drug effects ; Body Weight - drug effects ; Diabetes Mellitus, Experimental - complications ; Dose-Response Relationship, Drug ; Drinking - drug effects ; Drug toxicity and drugs side effects treatment ; Food ; Male ; Medical sciences ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Original Article ; Pharmacology. Drug treatments ; Piperazines - administration & dosage ; Rats ; Rats, Wistar ; Streptozocin ; Time Factors</subject><ispartof>European journal of anaesthesiology, 2002-07, Vol.19 (7), p.504-509</ispartof><rights>2002 European Society of Anaesthesiology</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Cambridge University Press Jul 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-49f7633922ed3af79419ad6ec4845f1d8c014a043ae92e56497c4a81f347dfb53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13734086$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12113613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Bucher, M.</creatorcontrib><creatorcontrib>Zimmermann, M.</creatorcontrib><creatorcontrib>Grobecker, H. F.</creatorcontrib><creatorcontrib>Krämer, B. K.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><title>Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat</title><title>European journal of anaesthesiology</title><addtitle>Eur J Anaesthesiol</addtitle><description>Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) receptor agonists impair glucose metabolism. To evaluate a possible dose-dependent hyperglycaemic effect of urapidil due to its 5-HT1A receptor agonistic properties, the effect of three doses of urapidil on hyperglycaemia in the streptozotocin diabetic rat was investigated. Methods: Male Wistar-Kyoto rats were made diabetic by streptozotocin and randomly allocated to the following daily treatments for 7 days (n = 6 each): urapidil 6 mg kg−1, urapidil 20 mg kg−1, urapidil 60 mg kg−1, insulin 4 IU kg−1 subcutaneously. One diabetic group and one non-diabetic healthy group served as controls. Results: Treatment for 7 days with urapidil 20 mg kg−1 and urapidil 60 mg kg−01 reduced mean glucose concentrations significantly (urapidil-20: 15.6 ± 1.1 mmol L−1P = 0.023; urapidil-60: 15.8 ± 0.8 mmol L−1, P = 0.04) compared with diabetic controls (20.9 ± 0.8 mmol L−1), whereas those after urapidil 6 mg kg−1 were similar to diabetic controls. Insulin treatment normalized blood glucose concentrations. Conclusions: The α1-adrenoceptor antagonist/5-HT1A receptor agonist urapidil has no hyperglycaemic effect on experimental diabetes mellitus, even in high doses, despite its 5-HT1A receptor agonistic properties.</description><subject>(RD) Surgery</subject><subject>Adrenergic alpha-Antagonists - administration & dosage</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Pressure - drug effects</subject><subject>Body Weight - drug effects</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drinking - drug effects</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Food</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - administration & dosage</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Streptozocin</subject><subject>Time Factors</subject><issn>0265-0215</issn><issn>1365-2346</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9r3DAQxUVJaDbbfoBcggg0Nyf6Z8k-lpCkhUAOSc9GlkZbLV5pK8mH5tNXSwwLLT0IwbzfezPMIHRByQ0lVN2-ECZbwmh9hJCOkQ9oRblsG8aFPEGrg9wc9DN0nvO2Mm31fURnlNHKUb5C4d45MAVHh8vPBICtr4UEoWAbM-SDMCe999ZPOAY8TjFavJlmU1VsYjAVTbr4GDL2oYYAziXBvsS3WKKpJev1CMUbXLFP6NTpKcPn5V-jHw_3r3ffmqfnx-93X58awzkpjeidkpz3jIHl2qle0F5bCUZ0onXUdoZQoYngGnoGrRS9MkJ31HGhrBtbvkbX77n7FH_NkMuw89nANOkAcc6Dol3PeasqePUXuI1zCnW2gVHZ9lJVbo3oO2RSzDmBG_bJ73T6PVAyHC4x_HOJ6rlcgudxB_boWFZfgS8LoLPRk0s6GJ-PHFdckE5Wji_N9W5M3m7gOOL_2_8BS6GfkA</recordid><startdate>20020701</startdate><enddate>20020701</enddate><creator>Ittner, K. P.</creator><creator>Bucher, M.</creator><creator>Zimmermann, M.</creator><creator>Grobecker, H. F.</creator><creator>Krämer, B. K.</creator><creator>Taeger, K.</creator><general>Cambridge University Press</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20020701</creationdate><title>Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat</title><author>Ittner, K. P. ; Bucher, M. ; Zimmermann, M. ; Grobecker, H. F. ; Krämer, B. K. ; Taeger, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-49f7633922ed3af79419ad6ec4845f1d8c014a043ae92e56497c4a81f347dfb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>(RD) Surgery</topic><topic>Adrenergic alpha-Antagonists - administration & dosage</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Pressure - drug effects</topic><topic>Body Weight - drug effects</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drinking - drug effects</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Food</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - administration & dosage</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Streptozocin</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Bucher, M.</creatorcontrib><creatorcontrib>Zimmermann, M.</creatorcontrib><creatorcontrib>Grobecker, H. F.</creatorcontrib><creatorcontrib>Krämer, B. K.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of anaesthesiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ittner, K. P.</au><au>Bucher, M.</au><au>Zimmermann, M.</au><au>Grobecker, H. F.</au><au>Krämer, B. K.</au><au>Taeger, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat</atitle><jtitle>European journal of anaesthesiology</jtitle><addtitle>Eur J Anaesthesiol</addtitle><date>2002-07-01</date><risdate>2002</risdate><volume>19</volume><issue>7</issue><spage>504</spage><epage>509</epage><pages>504-509</pages><issn>0265-0215</issn><eissn>1365-2346</eissn><coden>EJANEG</coden><abstract>Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) receptor agonists impair glucose metabolism. To evaluate a possible dose-dependent hyperglycaemic effect of urapidil due to its 5-HT1A receptor agonistic properties, the effect of three doses of urapidil on hyperglycaemia in the streptozotocin diabetic rat was investigated. Methods: Male Wistar-Kyoto rats were made diabetic by streptozotocin and randomly allocated to the following daily treatments for 7 days (n = 6 each): urapidil 6 mg kg−1, urapidil 20 mg kg−1, urapidil 60 mg kg−1, insulin 4 IU kg−1 subcutaneously. One diabetic group and one non-diabetic healthy group served as controls. Results: Treatment for 7 days with urapidil 20 mg kg−1 and urapidil 60 mg kg−01 reduced mean glucose concentrations significantly (urapidil-20: 15.6 ± 1.1 mmol L−1P = 0.023; urapidil-60: 15.8 ± 0.8 mmol L−1, P = 0.04) compared with diabetic controls (20.9 ± 0.8 mmol L−1), whereas those after urapidil 6 mg kg−1 were similar to diabetic controls. Insulin treatment normalized blood glucose concentrations. Conclusions: The α1-adrenoceptor antagonist/5-HT1A receptor agonist urapidil has no hyperglycaemic effect on experimental diabetes mellitus, even in high doses, despite its 5-HT1A receptor agonistic properties.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>12113613</pmid><doi>10.1017/S0265021502000820</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0265-0215 |
ispartof | European journal of anaesthesiology, 2002-07, Vol.19 (7), p.504-509 |
issn | 0265-0215 1365-2346 |
language | eng |
recordid | cdi_proquest_miscellaneous_71893357 |
source | MEDLINE; Journals@Ovid Complete |
subjects | (RD) Surgery Adrenergic alpha-Antagonists - administration & dosage Animals Biological and medical sciences Blood Glucose - drug effects Blood Pressure - drug effects Body Weight - drug effects Diabetes Mellitus, Experimental - complications Dose-Response Relationship, Drug Drinking - drug effects Drug toxicity and drugs side effects treatment Food Male Medical sciences Miscellaneous (drug allergy, mutagens, teratogens...) Original Article Pharmacology. Drug treatments Piperazines - administration & dosage Rats Rats, Wistar Streptozocin Time Factors |
title | Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-08T15%3A08%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20three%20different%20doses%20of%20urapidil%20on%20blood%20glucose%20concentrations%20in%20the%20streptozotocin%20diabetic%20rat&rft.jtitle=European%20journal%20of%20anaesthesiology&rft.au=Ittner,%20K.%20P.&rft.date=2002-07-01&rft.volume=19&rft.issue=7&rft.spage=504&rft.epage=509&rft.pages=504-509&rft.issn=0265-0215&rft.eissn=1365-2346&rft.coden=EJANEG&rft_id=info:doi/10.1017/S0265021502000820&rft_dat=%3Cproquest_cross%3E1495616271%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216596793&rft_id=info:pmid/12113613&rft_cupid=10_1017_S0265021502000820&rfr_iscdi=true |